Pacira BioSciences, Inc. (PCRX)
Return on total capital
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) (ttm) | US$ in thousands | -57,716 | -53,110 | 102,974 | 95,263 | 61,422 | 20,429 | 21,130 | 11,043 | 49,658 | 104,551 | 114,337 | 133,831 | 133,411 | 114,187 | 104,005 | 72,479 | 62,455 | 51,614 | 33,565 | 41,100 |
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 778,348 | 749,583 | 879,278 | 892,162 | 870,130 | 831,551 | 807,975 | 768,041 | 775,010 | 770,123 | 756,636 | 709,576 | 730,408 | 718,602 | 687,168 | 650,818 | 619,688 | 584,690 | 388,148 | 374,037 |
| Return on total capital | -7.42% | -7.09% | 11.71% | 10.68% | 7.06% | 2.46% | 2.62% | 1.44% | 6.41% | 13.58% | 15.11% | 18.86% | 18.27% | 15.89% | 15.14% | 11.14% | 10.08% | 8.83% | 8.65% | 10.99% |
December 31, 2024 calculation
Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $-57,716K ÷ ($—K + $778,348K)
= -7.42%
Pacira BioSciences, Inc.'s return on total capital has shown fluctuations over the period under review. The ratio increased steadily from 10.99% as of March 31, 2020, to a peak of 18.86% as of March 31, 2022. However, there was a notable decline in the ratio in the subsequent quarters, dropping to a low of 1.44% as of March 31, 2023.
Subsequently, the return on total capital showed some signs of recovery, reaching 11.71% as of June 30, 2024. However, there was a significant downturn in the last two quarters of 2024, with negative returns recorded, -7.09% and -7.42% as of September 30, 2024, and December 31, 2024, respectively.
The variability in Pacira BioSciences, Inc.'s return on total capital indicates potential fluctuations in the company's efficiency in generating returns from its total capital base. It is essential for stakeholders to monitor these fluctuations and understand the underlying factors driving the changes to assess the company's overall financial performance and sustainability.
Peer comparison
Dec 31, 2024